Molecular changes in smoking-related lung cancer

Expert Review of Molecular Diagnostics

Volumn 12, Issue 1, 2012, Pages 93-106

  Begum, Shahnaz ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DNA methylation; epigenetic alterations; epigenetics; genetic alterations; key pathways; lung cancer; miRNA; mutation; non small cell lung cancer; smoking

Indexed keywords

ACROLEIN; ANTIOXIDANT; APC PROTEIN; B RAF KINASE; CARBON MONOXIDE; CIGARETTE SMOKE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FRAGILE HISTIDINE TRIAD PROTEIN; HYDROCARBON; K RAS PROTEIN; MALOTILATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; NICOTINE; OXIDIZING AGENT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN P16; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR RUNX3;

CANCER PATIENT; CHROMOSOME 11P; CHROMOSOME 11Q; CHROMOSOME 12P; CHROMOSOME 13; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 1P; CHROMOSOME 2Q; CHROMOSOME 3; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 9; CHROMOSOME 9P; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CIGARETTE SMOKING; DNA METHYLATION; DOWN REGULATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HEREDITY; HISTONE MODIFICATION; HUMAN; INFLAMMATION; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULARLY TARGETED THERAPY; POINT MUTATION; PROMOTER REGION; REVIEW; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; GENETIC EPIGENESIS; GENETICS; LUNG TUMOR; METABOLISM; ONCOGENE; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING;

DISEASE PROGRESSION; ENVIRONMENTAL EXPOSURE; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; ONCOGENES; RISK FACTORS; SIGNAL TRANSDUCTION; SMOKING;

EID: 82955217696     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.84     Document Type: Review

References (130)

1. Begum S, Brait M, Dasgupta S et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17(13), 4494-4503 (2011).
2. Hoque MO, Brait M, Rosenbaum E et al. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer. J. Thorac. Oncol. 5(12), 1887-1893 (2010).
3. Ostrow KL, Hoque MO, Loyo M et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin. Cancer Res. 16(13), 3463-3472 (2010). Demonstrates that methylation frequencies of a panel of genes progressively increase with pack-per-year smoking.
4. Brait M, Ford JG, Papaiahgari S et al. Association between lifestyle factors and CpG island methylation in a cancer-free population. Cancer Epidemiol. Biomarkers Prev. 18(11), 2984-2991 (2009). Demonstrates methylation of some key genes in plasma of a high-risk cancer-free population.
5. Beer DG, Kardia SL, Huang CC et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8(8), 816-824 (2002).
6. Lu Y, Lemon W, Liu PY et al. A gene expression signature predicts survival of patients with Stage 1 non-small cell lung cancer. PLoS Med. 3(12), e467 (2006).
7. Xi L, Lyons-Weiler J, Coello MC et al. Prediction of lymph node metastasis by analysis of gene expression profiles in primary lung adenocarcinomas. Clin. Cancer Res. 11(11), 4128-4135 (2005).
8. Rizvi NA, Rusch V, Pao W et al. Molecular characteristics predict clinical outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene. Clin. Cancer Res. 17 (10), 3500-3506 (2011).
9. Adam T, Mitschke S, Streibel T, Baker RR, Zimmermann R. Quantitative puff-by-puff-resolved characterization of selected toxic compounds in cigarette mainstream smoke. Chem. Res. Toxicol. 19(4), 511-520 (2006).
10. Bernstein D. A review of the influence of particle size, puff volume, and inhalation pattern on the deposition of cigarette smoke particles in the respiratory tract. Inhal. Toxicol. 16(10), 675-689 (2004).
11. Valavanidis A, Vlachogianni T, Fiotakis K. Tobacco smoke: Involvement of reactive oxygen species and stable free radicals in mechanisms of oxidative damage, carcinogenesis and synergistic effects with other respirable particles. Int. J. Environ. Res. Public Health 6(2), 445-462 (2009).
12. Stewart SL, Cardinez CJ, Richardson LC et al. Surveillance for cancers associated with tobacco use-United States, 1999-2004. MMWR Surveill. Summ. 57(8), 1-33 (2008).
13. A Report of the Surgeon General. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease. Public Health Service Office of the Surgeon General, US Department of Health and Human Services, Rockville, MD, USA (2010).
14. Ng SP, Silverstone AE, Lai ZW, Zelikoff JT. Effects of prenatal exposure to cigarette smoke on offspring tumor susceptibility and associated immune mechanisms. Toxicol. Sci. 89(1), 135-144 (2006).
15. Yen CC, Liang SC, Jong YJ et al. Chromosomal aberrations of malignant pleural effusions of lung adenocarcinoma: Different cytogenetic changes are correlated with genders and smoking habits. Lung Cancer 57(3), 292-301 (2007).
16. Grepmeier U, Dietmaier W, Merk J et al. Deletions at chromosome 2q and 12p are early and frequent molecular alterations in bronchial epithelium and NSCLC of long-term smokers. Int. J. Oncol. 27(2), 481-488 (2005).
17. Haga Y, Hiroshima K, Iyoda A et al. Frequency of loss of heterozygosity at 3 p, 9 p, 13 q, and 17 p is related to proliferative activity in smokers with stage I non-small cell lung cancer. Thorac. Cardiovasc. Surg. 53(2), 114-117 (2005).
18. Marsit CJ, Wiencke JK, Nelson HH et al. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: Association with smoking, TP53, and survival. Cancer Genet. Cytogenet. 162(2), 115-121 (2005).
19. Pan H, Califano J, Ponte JF et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res. 65(5), 1664-1669 (2005).
20. Shin JH, Kang SM, Kim YS et al. Identification of tumor suppressor loci on the long arm of chromosome 5 in pulmonary large cell neuroendocrine carcinoma. Chest 128(4), 2999-3003 (2005).
21. Yohena T, Yoshino I, Takenaka T et al. Relationship between the loss of heterozygosity and tobacco smoking in pulmonary adenocarcinoma. Oncol. Res. 16(7), 333-339 (2007).
22. Pylkkanen L, Wolff H, Stjernvall T et al. Reduced Fhit protein expression and loss of heterozygosity at FHIT gene in tumours from smoking and asbestos-exposed lung cancer patients. Int. J. Oncol. 20(2), 285-290 (2002).
23. Yoshino I, Osoegawa A, Yohena T et al. Loss of heterozygosity (LOH) in non-small cell lung cancer: Difference between adenocarcinoma and squamous cell carcinoma. Respir. Med. 99(3), 308-312 (2005).
24. Mao L, Lee JS, Kurie JM et al. Clonal genetic alterations in the lungs of current and former smokers. J. Natl Cancer Inst. 857-862 (1997).
25. Anna L, Holmila R, Kovacs K et al. Relationship between TP53 tumour suppressor gene mutations and smoking-related bulky DNA adducts in a lung cancer study population from Hungary. Mutagenesis 24(6), 475-480 (2009).
26. Hagiwara N, Mechanic LE, Trivers GE et al. Quantitative detection of p53 mutations in plasma DNA from tobacco smokers. Cancer Res. 66(16), 8309-8317 (2006).
27. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 95(3), 197-204 (2004).
28. Pfeifer GP, Hainaut P. On the origin of G → T transversions in lung cancer. Mutat. Res. 526 (1-2), 39-43 (2003).
29. Le Calvez F, Mukeria A, Hunt JD et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: Distinct patterns in never, former, and current smokers. Cancer Res. 65(12), 5076-5083 (2005).
30. Hainaut P, Pfeifer GP. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22(3), 367-374 (2001).
31. Hussain SP, Amstad P, Raja K et al. Mutability of p53 hotspot codons to benzo(a) pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res. 61(17), 6350-6355 (2001).
32. Smith LE, Denissenko MF, Bennett WP et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J. Natl Cancer Inst. 92(10), 803-811 (2000).
33. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum. Mutat. 21(3), 229-239 (2003).
34. Husgafvel-Pursiainen K, Boffetta P, Kannio A et al. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 60(11), 2906-2911 (2000).
35. Vahakangas KH, Bennett WP, Castren K et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res. 61(11), 4350-4356 (2001).
36. Zhang S, Schafer-Hales K, Khuri FR et al. The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res. 68(3), 740-748 (2008).
37. Ji H, Ramsey MR, Hayes DN et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 448(7155), 807-810 (2007).
38. Shah U, Sharpless NE, Hayes DN. LKB1 and lung cancer: More than the usual suspects. Cancer Res. 68(10), 3562-3565 (2008).
39. Ghaffar H, Sahin F, Sanchez-Cepedes M et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin. Cancer Res. 9(8), 2998-3003 (2003).
40. Matsumoto S, Iwakawa R, Takahashi K et al. Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 26(40), 5911-5918 (2007).
41. Koivunen JP, Kim J, Lee J et al. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br. J. Cancer 99(2), 245-252 (2008).
42. Sanchez-Cespedes M, Decker PA, Doffek KM et al. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res. 61(5), 2092-2096 (2001).
43. Mikse OR, Blake DC Jr, Jones NR et al. FOXO3 encodes a carcinogen-Activated transcription factor frequently deleted in early-stage lung adenocarcinoma. Cancer Res. 70(15), 6205-6215 (2010).
44. Jin G, Kim MJ, Jeon HS et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69(3), 279-283 (2009).
45. Tam IY, Chung LP, Suen WS et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin. Cancer Res. 12(5), 1647-1653 (2006).
46. Fukuyama Y, Mitsudomi T, Sugio K et al. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br. J. Cancer 75(8), 1125-1130 (1997).
47. Westra WH. Early glandular neoplasia of the lung. Respir. Res. 1(3), 163-169 (2000).
48. Johnson L, Mercer K, Greenbaum D et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410(6832), 1111-1116 (2001).
49. Yang Y, Wislez M, Fujimoto N et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol. Cancer Ther. 7(4), 952-960 (2008).
50. Brose MS, Volpe P, Feldman M et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62(23), 6997-7000 (2002).
51. Dankort D, Filenova E, Collado M et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21(4), 379-384 (2007).
52. Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J. Clin. Oncol. 29(15), 2046-2051 (2011).
53. Krishnaswamy S, Kanteti R, Duke-Cohan JS et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin. Cancer Res. 15(18), 5714-5723 (2009).
54. Knudson A. Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68(4), 820-823 (1971).
55. Digel W, Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: Preclinical and clinical results. Crit. Rev. Oncol. Hematol. 55(1), 1-11 (2005).
56. Bowman RV, Yang IA, Semmler AB, Fong KM. Epigenetics of lung cancer. Respirology 11(4), 355-365 (2006).
57. Toyooka S, Suzuki M, Tsuda T et al. Dose effect of smoking on aberrant methylation in non-small cell lung cancers. Int. J. Cancer 110(3), 462-464 (2004).
58. Toyooka S, Maruyama R, Toyooka KO et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int. J. Cancer 103(2), 153-160 (2003).
59. Pulling LC, Divine KK, Klinge DM et al. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: More common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. Cancer Res. 63(16), 4842-4848 (2003).
60. Liu Y, Lan Q, Siegfried JM, Luketich JD, Keohavong P. Aberrant promoter methylation of p16 and MGMT genes in lung tumors from smoking and never-smoking lung cancer patients. Neoplasia 8(1), 46-51 (2006).
61. Wang YC, Lu YP, Tseng RC et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J. Clin. Invest. 111(6), 887-895 (2003).
62. Lee SJ, Jeon HS, Jang JS et al. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26(2), 403-409 (2005).
63. D'Alessio AC, Szyf M. Epigenetic tete-A-tete: The bilateral relationship between chromatin modifications and DNA methylation. Biochem. Cell Biol. 84(4), 463-476 (2006).
64. Lin RK, Hsu HS, Chang JW et al. Alteration of DNA methyltransferases contributes to 5ĆpG methylation and poor prognosis in lung cancer. Lung Cancer 55(2), 205-213 (2007).
65. Schrump DS, Hong JA, Nguyen DM. Utilization of chromatin remodeling agents for lung cancer therapy. Cancer J. 13(1), 56-64 (2007).
66. Belinsky SA, Nikula KJ, Baylin SB, Issa JP. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc. Natl Acad. Sci. USA 93(9), 4045-4050 (1996).
67. Xing J, Stewart DJ, Gu J et al. Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. Br. J. Cancer 98(10), 1716-1722 (2008).
68. Liu F, Killian JK, Yang M et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 29(25), 3650-3664 (2010). Indicates that cigarette smoke induces 'cancer-Associated' epigenomic alterations in cultured respiratory epithelia.
69. Van Den Broeck A, Brambilla E, Moro-Sibilot D et al. Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin. Cancer Res. 14(22), 7237-7245 (2008).
70. Hussain M, Rao M, Humphries AE et al. Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res. 69(8), 3570-3578 (2009). Provides evidence that cigarette smoke directly engages polycomb machinery to activate a signaling network implicated in maintenance of cancer stem cells.
71. Jensen TJ, Wozniak RJ, Eblin KE et al. Epigenetic mediated transcriptional activation of WNT5A participates in arsenical-Associated malignant transformation. Toxicol. Appl. Pharmacol. 235(1), 39-46 (2009).
72. Zhou X, Li Q, Arita A, Sun H, Costa M. Effects of nickel, chromate, and arsenite on histone 3 lysine methylation. Toxicol. Appl. Pharmacol. 236(1), 78-84 (2009).
73. Toyooka S, Tokumo M, Shigematsu H et al. Mutational and epigenetic evidence for independent pathways for lung adenocarcinomas arising in smokers and never smokers. Cancer Res. 66(3), 1371-1375 (2006).
74. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim. Biophys. Acta 1796(2), 114-128 (2009).
75. Damiani LA, Yingling CM, Leng S et al. Carcinogen-induced gene promoter hypermethylation is mediated by DNMT1 and causal for transformation of immortalized bronchial epithelial cells. Cancer Res. 68(21), 9005-9014 (2008). This finding supports the development of demethylation strategies for primary prevention of lung cancer in smokers.
76. Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res. 10(7), 2284-2288 (2004).
77. Valko M, Leibfritz D, Moncol J et al. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39(1), 44-84 (2007).
78. Thaiparambil JT, Vadhanam MV, Srinivasan C, Gairola CG, Gupta RC. Time-dependent formation of 8-oxo-deoxyguanosine in the lungs of mice exposed to cigarette smoke. Chem. Res. Toxicol. 20(12), 1737-1740 (2007).
79. van der Vaart H, Postma DS, Timens W, ten Hacken NH. Acute effects of cigarette smoke on inflammation and oxidative stress: A review. Thorax 59(8), 713-721 (2004).
80. Stampfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat. Rev. Immunol. 9(5), 377-384 (2009).
81. Rahman I, Kilty I. Antioxidant therapeutic targets in COPD. Curr. Drug Targets 7(6), 707-720 (2006).
82. Swarnam J, Sreekanth KS, Hareesh P, Sabu MC, Kuttan R. Effect of smoke shield-A herbal formulation on the mutagenicity and oxidative stress produced by cigarette smoke in rats. J. Exp. Clin. Cancer Res. 24(2), 297-304 (2005).
83. Comhair SA, Lewis MJ, Bhathena PR, Hammel JP, Erzurum SC. Increased glutathione and glutathione peroxidase in lungs of individuals with chronic beryllium disease. Am. J. Respir. Crit. Care Med. 159(6), 1824-1829 (1999).
84. Wang Y, Wang L, Ai X et al. Nicotine could augment adhesion molecule expression in human endothelial cells through macrophages secreting TNF-A, IL-1b. Int. Immunopharmacol. 4(13), 1675-1686 (2004).
85. Lim S, Roche N, Oliver BG et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Crit. Care Med. 162(4 pt 1), 1355-1360 (2000).
86. Ouyang Y, Virasch N, Hao P et al. Suppression of human IL-1b, IL-2, IFN-g, and TNF-Aproduction by cigarette smoke extracts. J. Allergy Clin. Immunol. 106(2), 280-287 (2000).
87. Zhang Q, Adiseshaiah P, Reddy SP. Matrix metalloproteinase/epidermal growth factor receptor/mitogen-Activated protein kinase signaling regulate fra-1 induction by cigarette smoke in lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 32(1), 72-81 (2005).
88. Li JM, Cui TX, Shiuchi T et al. Nicotine enhances angiotensin II-induced mitogenic response in vascular smooth muscle cells and fibroblasts. Arterioscler. Thromb. Vasc. Biol. 24(1), 80-84 (2004).
89. Mochida-Nishimura K, Surewicz K, Cross JV et al. Differential activation of MAP kinase signaling pathways and nuclear factor-kB in bronchoalveolar cells of smokers and nonsmokers. Mol. Med. 7(3), 177-185 (2001).
90. West KA, Brognard J, Clark AS et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Invest. 111(1), 81-90 (2003).
91. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3́-kinase/Akt pathway in vitro and in vivo. Cancer Res. 64(2), 446-451 (2004).
92. Tsurutani J, Castillo SS, Brognard J et al. Tobacco components stimulate Akt-dependent proliferation and NFkB-dependent survival in lung cancer cells. Carcinogenesis 26(7), 1182-1195 (2005).
93. Davidson MR, Larsen JE, Yang IA et al. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS One 5(90), e12560 (2010).
94. Schembri F, Sridhar S, Perdomo C et al. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl Acad. Sci. USA 106(7), 2319-2324 (2009). MicroRNA profiles obtained from this study may serve as biomarkers for smoking-related lung diseases and help elucidate the regulatory mechanisms that mediate the host response to tobacco smoke exposure and other environmental agents.
95. Wang XC, Tian LL, Wu HL et al. Expression of miRNA-130a in nonsmall cell lung cancer. Am. J. Med. Sci. 340(5), 385-388 (2010).
96. Gao W, Yu Y, Cao H et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed. Pharmacother. 64(6), 399-408 (2010).
97. Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin. Cancer Res. 16(2), 430-441 (2010).
98. Izzotti A, Calin GA, Arrigo P et al. Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. FASEB J. 23(3), 806-812 (2009).
99. Toyooka S, Matsuo K, Shigematsu H et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin. Cancer Res. 13(19), 5763-5768 (2007).
100. Thorgeirsson TE, Geller F, Sulem P et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452(7187), 638-642 (2008).
101. Hung RJ, McKay JD, Gaborieau V et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452(7187), 633-637 (2008).
102. McKay JD, Hung RJ, Gaborieau V et al. Lung cancer susceptibility locus at 5p15.33. Nat. Genet. 40(12), 1404-1406 (2008).
103. Amos CI, Wu X, Broderick P et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40(5), 616-622 (2008).
104. Hwang SJ, Cheng LS, Lozano G et al. Lung cancer risk in germline p53 mutation carriers: Association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum. Genet. 113(3), 238-243 (2003).
105. Spira A, Beane JE, Shah V et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat. Med. 13(3), 361-366 (2007). Indicates that gene expression in cytologically normal large-Airway epithelial cells can serve as a lung cancer biomarker, potentially owing to a cancer-specific airway-wide response to cigarette smoke.
106. Miura K, Bowman ED, Simon R et al. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res. 62(11), 3244-3250 (2002).
107. Abratt RP, Bezwoda WR, Falkson G et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: A Phase 2 study. J. Clin. Oncol. 12(8), 1535-1540 (1994).
108. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: Identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res. 60(21), 6116-6133 (2000).
109. Lodovici M, Luceri C, De Filippo C et al. Smokers and passive smokers gene expression profiles: Correlation with the DNA oxidation damage. Free Radic. Biol. Med. 43(3), 415-422 (2007).
110. Meneghini MD, Wu M, Madhani HD. Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell 112(5), 725-736 (2003).
111. Moodie FM, Marwick JA, Anderson CS et al. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kB activation and proinflammatory cytokine release in alveolar epithelial cells. FASEB J. 18(15), 1897-1899 (2004). Demonstrates alterations of key pathways by cigarette smoke.
112. Cucina A, Sapienza P, Borrelli V et al. Nicotine reorganizes cytoskeleton of vascular endothelial cell through platelet-derived growth factor BB. J. Surg. Res. 92(2), 233-238 (2000).
113. Smith CJ, Hansch C. The relative toxicity of compounds in mainstream cigarette smoke condensate. Food Chem. Toxicol. 38(7), 637-646 (2000).
114. Mishra NC, Rir-Sima-Ah J, Langley RJ et al. Nicotine primarily suppresses lung Th2 but not goblet cell and muscle cell responses to allergens. J. Immunol. 180(11), 7655-7663 (2008).
115. Kim JH, Kim H, Lee KY et al. Aryl hydrocarbon receptor gene polymorphisms affect lung cancer risk. Lung Cancer 56(1), 9-15 (2007).
116. Pae HO, Lee YC, Chung HT. Heme oxygenase-1 and carbon monoxide: Emerging therapeutic targets in inflammation and allergy. Recent Pat. Inflamm. Allergy Drug Discov. 2(3), 159-165 (2008).
117. Rahman I, van Schadewijk AA, Crowther AJ et al. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166(4), 490-495 (2002).
118. Barreiro E, Gea J, Matar G, Hussain SN. Expression and carbonylation of creatine kinase in the quadriceps femoris muscles of patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 33(6), 636-642 (2005).
119. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat. Rev. Cancer 9(3), 195-205 (2009).
120. Pfeifer GP, Denissenko MF, Olivier M et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-Associated cancers. Oncogene 21(48), 7435-7451 (2002).
121. Nelson HH, Wiencke JK, Gunn L et al. Chromosome 3p14 alterations in lung cancer: Evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res. 58(9), 1804-1807 (1998).
122. Sato S, Nakamura Y, Tsuchiya E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 54(21), 5652-5655 (1994).
123. Okuda K, Sasaki H, Hikosaka Y et al. LKB1 gene alterations in surgically resectable adenocarcinoma of the lung. Surg. Today 41(1), 107-110 (2010).
124. Lea IA, Jackson MA, Li X et al. Genetic pathways and mutation profiles of human cancers: Site- and exposure-specific patterns. Carcinogenesis 28(9), 1851-1858 (2007).
125. Hirao T, Nelson HH, Ashok TD et al. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res. 61(2), 612-615 (2001).
126. Yanagawa N, Tamura G, Oizumi H et al. Inverse correlation between EGFR mutation and FHIT, RASSF1A and RUNX3 methylation in lung adenocarcinoma: Relation with smoking status. Anticancer Res. 31(4), 1211-1214 (2011).
127. Buckingham L, Penfield Faber L, Kim A et al. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated Stage 1 and 2 nonsmall cell lung cancer patients. Int. J. Cancer 126(7), 1630-1639 (2010).
128. Beleford D, Liu Z, Rattan R et al. Methylation induced gene silencing of HtrA3 in smoking-related lung cancer. Clin. Cancer Res. 16(2), 398-409 (2010).
129. Nakata S, Sugio K, Uramoto H et al. The methylation status and protein expression of CDH1, p16 (INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: Epigenetic silencing, clinical features, and prognostic significance. Cancer 106(10), 2190-2199 (2006).
130. Kikuchi S, Yamada D, Fukami T et al. Hypermethylation of the TSLC1/IGSF4 promoter is associated with tobacco smoking and a poor prognosis in primary nonsmall cell lung carcinoma. Cancer 106(8), 1751-1758 (2006).